-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HkzUjjwvgwB1tcZ+X8MfJIQxbBz+oeGS+pzIVNQToc8Zu5JQen9d3vSLjnz0vDSz
 OLBIfzQzi8RYgFYiiMXyMQ==

<SEC-DOCUMENT>0001299933-09-003058.txt : 20090728
<SEC-HEADER>0001299933-09-003058.hdr.sgml : 20090728
<ACCEPTANCE-DATETIME>20090727174031
ACCESSION NUMBER:		0001299933-09-003058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090727
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090728
DATE AS OF CHANGE:		20090727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lifevantage Corp
		CENTRAL INDEX KEY:			0000849146
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841097796
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30489
		FILM NUMBER:		09965416

	BUSINESS ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-312-8000

	MAIL ADDRESS:	
		STREET 1:		11545 WEST BERNARDO COURT
		STREET 2:		SUITE 301
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIFELINE THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20041019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	YAAK RIVER RESOURCES INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANDRAPLEX CORP
		DATE OF NAME CHANGE:	19920406
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_33644.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Lifevantage Corporation (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	July 27, 2009
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Lifevantage Corporation
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Colorado
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	000-30489
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	90-0224471
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	11545 W. Bernardo Court, Suite 301, San Diego, California
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	92127
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	858-312-8000
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 2.02 Results of Operations and Financial Condition.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On July 27, 2009, Lifevantage Corporation issued a press release entitled, "Lifevantage Announces Preliminary Unaudited Fourth Quarter Revenue". The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 2.02 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language in such filing.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 7.01 Regulation FD Disclosure.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
On July 27, 2009, Lifevantage Corporation issued a press release entitled, "Lifevantage Announces Preliminary Unaudited Fourth Quarter Revenue". The press release is attached as Exhibit 99.1 hereto, which is furnished under Item 7.01 of this report and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, regardless of any general incorporation language in such filing.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
99.1 Press release, dated July 27, 2009, entitled, "Lifevantage Announces Preliminary Unaudited Fourth Quarter Revenue".
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Lifevantage Corporation
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	July 27, 2009
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	/s/ Carrie E. Carlander
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Carrie E. Carlander
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: Chief Financial Officer
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Lifevantage Announces Preliminary Unaudited Fourth Quarter Revenue
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt"><FONT style="font-size: 12pt"><B>LIFEVANTAGE ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER REVENUE</B></FONT>



<P align="center" style="font-size: 12pt"><FONT style="font-size: 11pt"><B>Company Anticipates 150% Increase in Net Revenue over Previous Quarter</B></FONT>



<P align="left" style="font-size: 11pt"><FONT style="font-size: 10pt"><B>San Diego</B>, <B>July&nbsp;27, 2009</B>, <U>LifeVantage Corporation (OTCBB: LFVN),</U> a science-based,
natural products company, dedicated to helping people reach their health and wellness goals through
science-based solutions to oxidative stress and a maker of Protandim<sup>&#174;</sup>, announced
preliminary unaudited net revenue for the fourth quarter of 2009. The Company anticipates net
revenue of approximately $1.6M for the three month period ended June&nbsp;30, 2009, which is an
approximate increase of 150% from the net revenue of approximately $0.65M for the three month
period ended March&nbsp;31, 2009. This substantial increase in revenue demonstrates the early results of
the Company&#146;s recent expansion into the network marketing distribution model.
</FONT>

<P align="left" style="font-size: 10pt">&#147;The increase in fourth quarter revenue is attributed to our launch earlier this year into
network marketing as well as the addition of a team of some of the most sought after and highest
producing independent distributors in the network marketing industry. We believe this team will
continue to significantly impact LifeVantage&#146;s continued expansion into the network marketing sales
channel,&#148; stated David W. Brown, LifeVantage President & CEO.


<P align="left" style="font-size: 10pt"><B>About LifeVantage Corporation</B>
<BR>
LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, natural products
company, dedicated to helping people reach their health and wellness goals through science-based
solutions to oxidative stress. Founded in 2003 and based in San Diego, CA, LifeVantage develops
nutraceutical products, including Protandim<sup>&#174;</sup>, that leverage the company&#146;s expertise and
that are intended to deliver significant health benefits to consumers. For more information, visit
<U>www.LifeVantage.com</U>.


<P align="left" style="font-size: 10pt"><B>About Protandim&#174;</B>
<BR>
Protandim<sup>&#174;</sup> is a groundbreaking, clinically proven supplement that provides substantial
benefits to help with the challenges of healthy aging. This patented antioxidant therapy works in a
very different way than conventional foods such as red wine, oranges, blueberries or other popular
antioxidant supplements; as a result, according to Dr.&nbsp;Joe McCord, it is much more effective than
those products or foods in reducing oxidative stress. Protandim<sup>&#174;</sup> works by increasing the
body&#146;s natural antioxidant protection at the cellular level, triggering (inducing)&nbsp;cells to produce
naturally occurring protective antioxidant enzymes such as superoxide dismutase (SOD), catalase,
and glutathione synthase. Dr.&nbsp;McCord is a pioneer scientist in the field of oxidative stress and is
on the Company&#146;s Board of Directors.


<P align="left" style="font-size: 10pt">A peer-reviewed human clinical study showed that after Protandim<sup>&#174;</sup> was taken for 30
consecutive days, the accumulation of lipid peroxidation products (a biochemical marker of aging)
was decreased by an average of 40%, although that reduction may be not be typical for all those who
consume the product. The study also reported that this important marker of aging was decreased
after taking Protandim<sup>&#174;</sup> to the level of a typical 20&nbsp;year old. Protandim<sup>&#174;</sup> is
currently the subject of&nbsp;approximately 20 scientific studies at leading universities and research
facilities. The nature and stages of the studies vary, as some of the testing is at the preliminary
stage, while other studies&nbsp;using Protandim<sup>&#174;</sup> are currently in&nbsp;progress. For more
information about Protandim<sup>&#174;</sup>, visit <U>www.LifeVantage.com</U>.


<P align="left" style="font-size: 10pt"><B>About </B><B><I>LifeVantage TrueScience</I></B><B>&#153; Anti-Aging Cream</B>
<BR>
<I>LifeVantage TrueScience</I><sup><I>&#153;</I></sup> is scientifically-based and contains cutting-edge ingredients,
including those found in Protandim<sup>&#174;</sup>. <I>LifeVantage TrueScience</I><sup><I>&#153;</I></sup> Anti-Aging
Cream gives skin a beautiful, even and smooth tone, diminishing fine lines and wrinkles, and
providing a vibrant and glowing appearance. <I>LifeVantage TrueScience</I><sup><I>&#153;</I></sup> also improves skin
smoothness and pigmentation, while increasing skin moisture. For more information about
<I>LifeVantage TrueScience</I><sup><I>&#153;</I></sup>, visit <U>www.LifeVantage.com</U>.


<P align="left" style="font-size: 10pt"><B>Unaudited Financial Information.</B>
<BR>
This announcement contains historical financial information for the three-month periods ended June
30, 2009 and June&nbsp;30, 2008 that is unaudited and Lifevantage assumes no obligation to update this
information based on new information or future performance except as may be specifically required
by applicable law or regulation. The unaudited financial information is subject to audit by
independent accountants on an annual basis following the close of each calendar year. Such an audit
is currently ongoing and the unaudited information presented in this announcement as of and for the
three months ended June&nbsp;30, 2009 is subject to adjustment based on the results of the audit.
Accordingly, the financial information that will be reported in Lifevantage&#146;s Annual Report on Form
10-K for the year ended June&nbsp;30, 2009 may vary from the financial information presented in this
announcement.


<P align="left" style="font-size: 10pt"><B>Forward Looking Statements</B>
<BR>
This document contains forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The Company uses the words &#147;anticipate,&#148;
&#147;believe,&#148; &#147;could,&#148; &#147;should,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;plan,&#148;
&#147;target&#148; and similar terms and phrases, including references to assumptions, to identify
forward-looking statements. These forward-looking statements are based on the Company&#146;s current
expectations and beliefs concerning future events affecting the Company and involve known and
unknown risks and uncertainties that may cause the Company&#146;s actual results or outcomes to be
materially different from those anticipated and discussed herein. These risks and uncertainties
include, among others, the potential failure or unintended negative consequences of the
implementation of our network marketing sales channel; our ability to retain independent
distributors or to attract new independent distributors on an ongoing basis;</FONT><FONT style="font-size: 12pt"> </FONT><FONT style="font-size: 10pt">the
potential for third party and governmental actions involving our network marketing sales channel;
the potential for product liability claims against the Company; the risk that&nbsp;government regulators
and regulations could adversely affect our business; future laws or regulations may hinder or
prohibit the production or sale of our existing product and any future products; unfavorable
publicity could materially hurt our business; and the Company&#146;s ability to protect our intellectual
property rights and the value of our product. These and other risk factors are discussed in
greater detail in the Company&#146;s Annual Report on Form 10-KSB and Quarterly Report on Form 10-Q
under the caption &#147;Risk Factors&#148;, and in other documents filed the Company from time to time with
the Securities and Exchange Commission. The Company cautions investors not to place undue reliance
on the forward-looking statements contained in this document. All forward-looking statements are
based on information currently available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking statements to reflect events or
circumstances after the date of this document, except as required by law.
<BR>
*These statements have not been evaluated by the Food and Drug Administration. This product is not
intended to diagnose, treat, cure or prevent any disease.
</FONT>


<P align="left" style="margin-left:21%; font-size: 10pt; text-indent: 4%">###


<P align="left" style="font-size: 10pt">Note to Editors: Contact Jan Strode at 619-890-4040 or Jean Golden 612-385-2324 for interviews,
photography, and other requests.


<P align="left" style="font-size: 10pt"><B>Investor Contact:</B>
<BR>
Ioana C. Hone
<BR>
(858)&nbsp;312-8016


<P align="left" style="font-size: 10pt"><B>Media Contact:</B>
<BR>
For LifeVantage Corporation
<BR>
Jan Strode, 619-890-4040
<BR>
or
<BR>
Jean Golden, 612-385-2324



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
